NRx Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and reporting period
Quarterly report for the three and nine months ended September 30, 2022, filed November 14, 2022. NRx is a clinical-stage pharmaceutical company with no commercial revenue. Its primary focus is NRX-101, an investigational therapy for bipolar depression with suicidal ideation following ketamine stabilization. NRX-101 has FDA Fast Track and Breakthrough Therapy designations, a Special Protocol Agreement, and a Biomarker Letter of Support. The company also disclosed plans to investigate PTSD.
Financial position and key metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | No revenue | No revenue |
| Research and development expense | $4.1 million, versus $6.3 million | $12.6 million, versus $13.8 million |
| General and administrative expense | $5.0 million, versus $13.8 million | $21.9 million, versus $28.4 million |
| Operating loss | $9.1 million, versus $20.1 million | $34.4 million, versus $62.8 million |
| Net loss | $9.1 million, versus $37.0 million | $29.5 million, versus $62.7 million |
| Net loss per share | $0.14 | $0.45 |
| Net cash used in operating activities | Not provided for the quarter | $31.4 million, versus $26.4 million |
- Cash and cash equivalents were $18.2 million at September 30, 2022, down from $27.6 million at December 31, 2021.
- Total assets were $24.8 million and total liabilities were $8.0 million at September 30, 2022. Stockholders’ equity was $16.8 million.
- The company had no note payable outstanding at September 30, 2022; warrant liabilities were $56,000.
- Operating cash consumption increased despite the lower net loss, reflecting fewer large non-cash charges in 2022. Net cash provided by financing activities was $22.1 million, primarily from the February private placement.
- Operating and net margins are not meaningful because the company has no revenue and remains loss-making.
Material changes versus the prior comparable period
- Third-quarter net loss declined by $28.0 million, primarily because 2021 included a $16.5 million warrant-liability loss and substantially higher consulting and other general and administrative expenses.
- Nine-month net loss declined by $33.1 million. The prior-year period included $21.4 million of non-cash settlement expense related to the GEM warrant and $12.8 million of non-cash consulting expense.
- Research and development expense decreased mainly because of lower ZYESAMI clinical-trial and development costs.
- General and administrative expense decreased, largely because of lower consultant fees and stock-based compensation, partly offset by higher legal, professional, accounting, insurance, payroll, and salary expenses.
- On February 2, 2022, the company issued 7.8 million common shares and options to purchase 7.8 million shares in a private placement, generating approximately $22.6 million of net proceeds. Shares outstanding increased to 67.6 million by September 30, 2022 from 58.8 million at December 31, 2021.
- The Earnout Cash liability was reduced from $4.6 million at year-end 2021 to zero at September 30, 2022 because management assessed the required milestones as having a de minimis probability of achievement.
Guidance, outlook, risks, contingencies, and unusual items
- Management planned to initiate the registrational Phase 3 NRX-101 trial in the fourth quarter of 2022, with a data readout expected in the third quarter of 2023 and a potential NDA submission by year-end 2023 if efficacy and safety endpoints are met. These are forward-looking plans, not assurances.
- The company stated that it expects continued operating losses and negative operating cash flows and may never become profitable. It expects to require additional equity and/or debt financing.
- On November 4, 2022, after the reporting date, the company issued an 9% redeemable promissory note with $11.0 million principal and $10.0 million of net proceeds. The note matures in 18 months and permits monthly redemptions of up to $1.0 million beginning six months after issuance, potentially payable in cash, stock, or a combination. The redemption price is based on a formula incorporating a 15% discount to specified trading prices, creating potential dilution and liquidity risk.
- On November 12, 2022, the company entered into a settlement and asset purchase agreement with Relief Therapeutics. Subject to closing, NRx will transfer its interests in ZYESAMI, including related intellectual property, regulatory applications, clinical data, inventory, and contractual rights. Potential consideration includes milestone payments of up to $13.0 million and royalties capped at $30.0 million in aggregate; commercialization is not assured.
- GEM demanded arbitration for an approximately $1.9 million commitment fee. NRx disputes that the fee is owed and intends to defend the claim.
- The company disclosed ineffective disclosure controls and a material weakness in internal control over financial reporting related to review procedures for complex warrant transactions. The weakness resulted in a restatement to reclassify Substitute Warrants.
- Key development risks include clinical-trial failure, regulatory non-approval, manufacturing and third-party dependence, protection of intellectual property, limited cash resources, future dilution, litigation, and the absence of product revenue.
Important facts for investors to verify
- Whether the NRX-101 Phase 3 trial actually commenced on the stated timeline and whether enrollment, design, costs, and regulatory interactions remain consistent with management’s plans.
- Current cash runway after the November 2022 financing, including the note’s redemption terms, interest burden, acceleration provisions, and potential stock settlement dilution.
- Closing and final terms of the Relief Therapeutics settlement and asset transfer, including any continuing obligations, milestone conditions, royalties, and indemnity exposure.
- Status, estimated exposure, and potential outcome of the GEM arbitration.
- Remediation of the material weakness and whether subsequent filings report effective disclosure controls and internal control over financial reporting.
- Remaining warrants, options, restricted shares, and contingent earnout interests, including their potential dilution to common stockholders.